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Abstract
Background: The Epstein-Barr virus (EBV) is associated with lymphoid malignancies, including
Burkitt's lymphoma (BL), and can transform human B cells in vitro. EBV-harboring cell lines are
widely used to investigate lymphocyte transformation and oncogenesis. Qualitative EBV gene
expression has been extensively described, but knowledge of quantitative transcription is lacking.
We hypothesized that transcription levels of EBNA1, the gene essential for EBV persistence within
an infected cell, are similar in BL cell lines.
Results: To compare quantitative gene transcription in the BL cell lines Namalwa, Raji, Akata,
Jijoye, and P3HR1, we developed an oligonucleotide microarray chip, including 17 housekeeping
genes, six latent EBV genes (EBNA1, EBNA2, EBNA3A, EBNA3C, LMP1, LMP2), and four lytic EBV
genes (BZLF1, BXLF2, BKRF2, BZLF2), and used the cell line B95.8 as a reference for EBV gene
transcription. Quantitative polymerase chain reaction assays were used to validate microarray
results. We found that transcription levels of housekeeping genes differed considerably among BL
cell lines. Using a selection of housekeeping genes with similar quantitative transcription in the
tested cell lines to normalize EBV gene transcription data, we showed that transcription levels of
EBNA1 were quite similar in very different BL cell lines, in contrast to transcription levels of other
EBV genes. As demonstrated with Akata cells, the chip allowed us to accurately measure EBV gene
transcription changes triggered by treatment interventions.
Conclusion: Our results suggest uniform EBNA1 transcription levels in BL and that microarray
profiling can reveal novel insights on quantitative EBV gene transcription and its impact on
lymphocyte biology.
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Background
The B-cell-tropic Epstein-Barr virus (EBV) is associated
with lymphoid malignancies, including Burkitt's lym-
phoma (BL), Hodgkin's disease, and post-transplant lym-
phoproliferative disease [1]. Consistent with its role as a
tumor virus, EBV can transform human B cells in vitro [2],
and EBV-harboring cell lines constitute a key research tool
to study pathogenic events leading to lymphocyte trans-
formation and oncogenesis.
As noted in studies of tumors and cell lines, expression of
latent EBV genes contributes to cell transformation, and
these studies have resulted in the description of three EBV
latency programs [3,4]. The latency I program expresses
the EBV nuclear antigen (EBNA) 1 gene and is characteris-
tic of BL. The latency II program expresses EBNA1 plus the
latent membrane proteins (LMP) 1 and LMP2 and is seen
in Hodgkin's disease and the epithelial malignancy
nasopharyngeal carcinoma. The latency III program
involves expression of all six EBNAs, LMP1, 2A, and 2B,
and EBV-encoded RNAs. It is found in EBV-driven lym-
phoproliferations of the immunocompromised host and
in EBV-transformed lymphoblastoid cell lines (LCLs).
Recently, an EBV gene expression program that closely
matches the EBV growth-promoting latency III program
was reported in a subset of BL [5]. Notably, latent EBV
infection can be disrupted by expression of the master reg-
ulator lytic EBV gene BZLF1 that initiates EBV replication,
ultimately resulting in the assembly of new EBV particles
and their release upon cell lysis [6,7]. This observation
ignited great interest in a possible new therapeutic strategy
against EBV-harboring tumors: inducing lytic EBV infec-
tion with subsequent cell lysis [8].
Quantitative characterization of EBV gene transcription
would allow a more in-depth analysis of the patterns and
dynamics of EBV gene transcription in different cellular
backgrounds that, in turn, could reveal important regula-
tory mechanisms governing the maintenance of EBV
latent infection, host cell transformation, and reactivation
of lytic infection. Thus, a research tool to quantify simul-
taneous EBV gene transcription is desirable. Unfortu-
nately, although EBV gene expression in EBV-infected cell
lines has been studied extensively, only non- or semi-
quantitative methods, such as Northern blotting or South-
ern reverse-transcription polymerase chain reaction (PCR)
assays, have been used [4] and, little is known about the
quantitative EBV gene transcription levels in infected B-
cells.
We hypothesized that the transcription levels of EBNA1,
the EBV gene essential for EBV persistence in the infected
cell, are similar in rather different BL cell lines. To test this
hypothesis, we developed an EBV oligonucleotide (ODN)
microarray chip applicable to different cellular back-
grounds and used it to perform comparative quantifica-
tion of latent and lytic EBV gene transcription normalized
to housekeeping genes in a limited set of EBV-harboring
BL cell lines.
Results
Selecting housekeeping genes to normalize EBV gene 
transcription in BL cell lines
The first step in quantifying gene transcription is to iden-
tify genes that can be used as controls. Internal control
genes, often referred to as housekeeping genes, should not
vary among the tissues or cells under investigation. Unfor-
tunately, considerable variability has been reported in the
transcription of many housekeeping genes [9,10].
To build our microarray chip, we started with housekeep-
ing genes derived from two groups of the Human Gene
Expression Index (HuGE) [9] and for which probes were
already described in the Church set of human probes [11].
We began with those with either the highest transcription
levels (e.g., RPL37A, KIAA0220, CLU, MT2A, FTL) or the
most constant transcription (e.g., PSMD2, PSMB3, TCFL1,
H3F3A, PTDSS1, KARS, AAMP, 384D8-2). In addition, we
included commonly used housekeeping genes (ACTB, c-
yes, MHCL, HMBS) [12] (Table 1A).
Next we determined the suitability of the genes for our
assay. The marmoset cell line B95.8 was selected as the ref-
erence line because it expresses all of the latent genes and
most of the lytic EBV genes under normal culture condi-
tions [13]. B95.8 is of primate origin, and we focused par-
ticularly on probes derived from human housekeeping
gene sequences that would hybridize with the same effi-
ciency to B95.8 gene sequences. RNAs from human BL cell
lines (e.g., BJAB, Namalwa, Raji, Akata, Jijoye, and
P3HR1) were used in self-vs-self hybridizations. Tran-
scription levels for 13 of 17 housekeeping genes were
detected over background in these cell lines, and 12
housekeeping genes showed levels similar to those found
in B95.8 cells (Table 2). The coefficient of variation (CV),
calculated as the ratio of the standard deviation (SD) to
the mean of the transcription detected in all cell lines
tested, ranged from 0.17 for ACTB to 2.24 for CLU. Probes
with a CV > 0.5 were eliminated. Probes with a mean tran-
scription signal > two SD and significant transcription in
B95.8 were selected for the normalization housekeeping
gene set. Using these criteria, we identified eight house-
keeping genes PSMD2, PSMB3, TCLF1, PTDSS1, AAMP,
ACTB, c-yes, and HMBS for the normalization housekeep-
ing gene set (Table 2).
Selection of EBV-specific probes
During latency, EBV expresses a limited set of the 85 pre-
dicted open reading frames from its genome [14]. SevenV
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Table 1A: Probes for housekeeping genes
Oligo Name Unigene nt Transcript 
Length (nt)
Distance 
from 3' (nt)
Tm (°C) GC (%) Design Sense Probe Sequence (5' to 3')
RPL37A Hs.433701 70 1059 607 78.3 50.0 CS AGGCCTTCCCGAGAAAGTGCTTAGCCTTGTTGATGATCCAAGGAACCACAT
AGAGAACCAAGACGAGTGC
KIAA0220 Hs.110613 70 1121 416 82.4 60.0 CS TGGAACCATCATCACCCGAACCCAAGAGGCGGAGGGTCGGTGACGTGGAA
CCGTCACGCAAACCCAAGAG
CLU Hs.75106 70 1676 903 82.4 60.0 CS TTTCCCAAGTCCCGCATCGTCCGCAGCTTGATGCCCTTCTCTCCGTACGAG
CCCCTGAACTTCCACGCCA
MTA2 Hs.118786 70 1929 154 78.8 51.4 CS GCAAGAAGTTACGACACGTACACAACGACAGAACAACAGAGAAGACCCCG
AAGACCACTAGCACGACCGT
384D8-2.2 Hs.356523 71 2281 334 80.6 52.2 CS CGAAGGAAAGTGGAGCTCTTCATCGCCACCTCCCAGAAGTTTATCCAGGAG
ACAGAGCTGAGCCAGCGCA
FTL Hs.118786 70 1929 154 78.8 51.4 CS CTCTCTCTTTCAGGCCTCAACAGGCACTGTATTCATTGCCAATGTTCCAAAT
TATCAAATTCAAGTGAAT
PSMD2 Hs.74619 70 2828 122 75.9 44.3 CS TATCTTCGGAAGAACCCCAATTATGATCTCTAAGTGACCACCAGGGGCTCT
GAACTGTAGCTGATGTTAT
PSMB3 Hs.82793 70 692 42 79.4 52.8 CS ATCATCGAGAAGGACAAAATCACCACCAGGACACTGAAGGCCCGAATGGA
CTAACCCTGTTCCCAGAGCC
T CFL1 Hs.2430 70 1324 153 76.5 46.2 CS CCCCGAGCCTTGCGCCAGAAAATTGTCATTAAATGAAGAGATGTCTAGTCC
TCAGAAACTTCTTTCCTGC
H3F3A Hs.181307 70 1305 20 73.6 38.5 CS GAGTTGTCCTACATGCAAGTACATGTTTTTAATGTTGTCTGTCTTCTGTGCT
GTTCCTGTAAGTTTGCTA
PTDSS1 Hs.77329 70 2504 242 77.7 48.6 CS GTAGCTGCCTGCATAGGAGCCTCGCTTCCGATTATTCCCTTCCCAATATTAT
TCATCCAGACTTAGCCAC
KARS Hs.3100 70 1997 142 73.6 38.6 CS GCAACCACTGATACACTGGAAAGCACAACAGTTGGCACTTCTGTCTAGAAA
ATAATAATTGCAAGTTGTA
AAMP Hs.83347 70 1762 622 81.2 57.1 CS ACCTTGGCCATCTATGACCTGGCTACGCAGACTCTTAGGCATCAGTGTCAG
CACCAGTCGGGCATCGTGC
β-actinsense Hs.288061 68 1841 431 92.7 50.0 PE TTAAAAACTGGAACGGTGAAGGTGACAGCAGTCGGTTGGAGCGAGCATCC
CCCAAAGTTCACAATGTG
β-actin.70 mer Hs.288061 71 1841 700 96.0 56.3 PE CCTGGCACCCAGCACAATGAAGATCAAGATCATTGCTCCTCCTGAGCGCAA
GTACTCCGTGTGGATCGGCG
c-yes.70 mer Hs.194148 70 4343 1249 96.7 62.9 PE CTCGGCTCACTGCAAGCTCTGCCTCCCAGGTTCACACCATTCTCCTGCCTC
AGCCTCCCGAGTAGCTGGG
c-yes.2 Hs.194148 70 539 73.6 52.2 CS CATGCAAGTTGGCAGTGGTTCTGGTACTAAAAATTGTGGTTGTTTTTTCTGT
TTACGTAACCTGCTTAGT
MHCI.70 mer Hs.379218 70 2290 600 92.7 55.7 PE CTCAGATAGAAAAGGAGGGAGCTACTCTCAGGCTGCAAGCGGCAACAGTG
CCCAGGGCTCTGATGTGTCT
HMBS.70 mer Hs.82609 70 1536 1300 97.7 57.0 PE ACGGCAATGCGGCTGCAACGGCGGAAGAAAACAGCCCAAAGATGAGAGTG
ATTCGCGTGGGTACCCGCAA
HMBS.2 Hs.82609 70 164 82.4 52.2 CS TGCTGTCCAGTGCCTACATCCCGGGCCTCAGTGCCCCATTCTCACTGCTAT
CTGGGGAGTGATTACCCCG
EF1.70 mer Hs.181165 71 1833 500 91.8 50.7 PE GGCAAGCCCATGTGTGTTGAGAGCTTCTCAGACTATCCACCTTTGGGTCGC
TTTGCTGTTCGTGATATGAG
CS: Church set; PE: Primer ExpressV
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Table 1B: Probes for Epstein-Barr Virus genes
Oligo Name nt Transcript
Length (bp)
Distance from
3' (bp)
Tm (°C) GC (%) Design Sense Probe Sequence (5' to 3')
EBNA1_AD.1 60 1131 202 76.1 45.0 AD TTTGAAGGATGCGATTAAGGACCTTGTTATGACAAAGCCCGCTCCTACCTGCAATATCAG
EBNA1_AD.2 60 1131 803 79.0 55.0 AD GAGAGGTCGTGGACGTGGAGAAAAGAGGCCCAGGAGTCCCAGTAGTCAGTCATCATCATC
EBNA2_AD.1 60 1464 687 79.0 53.3 AD GCACCCTCTTACTCATCAAAGCACCCCAAATGATCCAGATAGTCCAGAACCACGGTCCCC
EBNA3A_AD.1 60 1360 29 76.9 48.3 AD GAAGCCATTCTCCGCAGGTTTCCACTAGATCTAAGAACACTTCTTCAAGCGATTGGAGCC
EBNA3C_AD.1 60 2973 129 79.2 53.3 AD GACCTGCCCGGTGTTCCCAAGCTACTGCTGAAGCACAGGAGATTCTCAGTGACAATTCTG
EBNA3C_AD.2 60 2973 893 79.1 51.7 AD TAAGGCCCAGCCCATAGAAAGTTCACACTTGAGTTCCATGTCGCCCACACAGCCGATATC
LMP1.70 mer 70 2038 813 88.3 47.1 PE CTGTTCATCTTTGGCTGCTTACTTGTCTTCGGTATCTGGATCTACTTCTTGGAGATTCTCTGGCGG
CTTG
LMP 2A&2B.70 mer 70 1196 53 94.5 54.3 PE CCGACCCCATATCGCAACACTGTATAAAGAATGCCCACCAGATCGCCTGCCACTTCCACAGCAA
TGGCAC
LMP2_AD.1 60 1196 199 77.0 48.3 AD AATGGCGACCGTCACTCGGACTATCAACCACTAGGAACCCAAGATCAAAGTCTGTACTTG
BZLF1.70 mer 70 1767 280 90.3 47.1 PE ACGCACACGGAAACCACAACAGCCAGAATCGCTGGAGGAATGCGATTCTGAACTAGAAATAAAG
CGATAC
gp85.70 mer 70 2121 90 93.3 51.4 PE TCCACGTTCACTATCTGCTGCTGACCACCAACGGGACTGTCATGGAAATTGCGGGCCTGTATGA
AGAAAGAG
gp85_AD.1 60 2121 491 76.8 48.3 AD ATTATCCCGCTCATCAATGTGACATTCATAATCTCTAGTGACCGTGAGGTCCGAGGCTCG
gL_AD.1 60 414 294 77.7 48.3 AD CGCGTTGGAAAACATTAGCGACATTTACCTGGTGAGCAATCAGACATGCGACGGCTTTAG
g42_AD.1 60 672 259 76.0 46.7 AD CAACGCCCGATATTCTACCTGTGGTAACTAGAAATCTGAATGCCATTGAGTCCCTTTGGG
AD: ArrayDesign; PE: Primer ExpressV
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Table 2: Expression profiles of 17 housekeeping genes in a panel of cell lines
B95.8 BJAB Namalwa Raji Akata Jijoye P3HR1 All cell lines
High expression Mean SD CV Mean SD CV Mean SD CV Mean SD CV Mean SD CV Mean SD CV Mean SD CV Mean SD CV
RPL37A 0.36 0.05 0.15 0.33 0.02 0.06 1.31 0.18 0.14 0.27 0.21 0.76 1.69 0.02 0.01 2.05 0.01 0.01 1.35 0.05 0.04 1.10 0.68 0.62
KIAA0220 0.06 0.01 0.12 2.33 0.60 0.26 1.56 0.07 0.05 2.98 0.79 0.27 1.64 0.03 0.02 2.02 0.01 0.01 1.37 0.02 0.01 1.63 0.87 0.54
CLU 1.62 0.02 0.01 0.21 0.04 0.21 0.06 0.03 0.41 n.d. 0.00 0.13 0.04 0.33 0.20 0.06 0.28 0.20 0.02 0.12 0.26 0.59 2.24
MTA2 0.00 0.01 12.49 0.02 0.02 1.13 n.d. 0.00 n.d. 0.00 n.d. 0.00 n.d. 0.00 n.d. 0.00
384D8-2.2 0.27 0.05 0.17 0.32 0.04 0.13 0.35 0.04 0.11 n.d. 0.00 0.36 0.06 0.16 0.70 0.21 0.30 0.64 0.04 0.07 0.29 0.43 1.47
Constant 
expression
Mean SD CV Mean SD CV Mean SD CV Mean SD CV Mean SD CV Mean SD CV Mean SD CV Mean SD CV
FTL 1.49 0.08 0.05 0.20 0.01 0.05 0.10 0.05 0.54 n.d. 0.00 0.33 0.12 0.36 0.51 0.25 0.49 0.75 0.10 0.13 0.45 0.59 1.31
PSMD2 0.89 0.04 0.04 2.38 0.67 0.28 1.08 0.05 0.04 0.24 0.01 0.06 1.67 0.02 0.01 1.46 0.20 0.14 1.04 0.15 0.14 1.22 0.63 0.52
PSMB3 1.49 0.02 0.01 2.35 0.62 0.27 1.61 0.12 0.08 0.62 0.22 0.36 1.70 0.00 0.00 2.03 0.00 0.00 1.35 0.04 0.03 1.57 0.51 0.33
TCLF1 0.53 0.02 0.03 0.72 0.01 0.02 1.43 0.13 0.09 0.20 0.06 0.30 0.51 0.21 0.42 1.26 0.32 0.25 1.18 0.11 0.09 0.90 0.40 0.52
H3F3A 1.71 0.03 0.02 2.44 0.76 0.31 1.64 0.13 0.08 7.38 4.68 0.63 1.69 0.00 0.00 2.08 0.01 0.01 1.35 0.04 0.03 2.44 2.03 0.83
PTDSS1 1.40 0.00 0.00 2.45 0.76 0.31 1.51 0.07 0.04 4.87 1.42 0.29 0.95 0.02 0.02 1.92 0.09 0.05 1.35 0.03 0.02 1.98 1.25 0.53
KARS 1.19 0.03 0.03 2.45 0.77 0.31 1.62 0.12 0.07 6.40 3.35 0.52 1.66 0.02 0.01 2.08 0.01 0.00 1.35 0.05 0.03 2.22 1.75 0.79
AAMP 0.57 0.01 0.02 0.62 0.01 0.01 0.59 0.04 0.07 0.13 0.04 0.31 0.55 0.07 0.12 1.00 0.18 0.18 1.29 0.02 0.01 0.71 0.35 0.50
Common Mean SD CV Mean SD CV Mean SD CV Mean SD CV Mean SD CV Mean SD CV Mean SD CV Mean SD CV
βactin.sense
(ACTB)
1.73 0.04 0.02 1.68 0.28 0.17 1.21 0.07 0.06 2.28 0.23 0.10 0.78 0.13 0.16 1.72 0.24 0.14 1.34 0.01 0.00 1.49 0.46 0.31
βactin.70 
mer(ACTB)
1.69 0.02 0.01 1.00 0.24 0.24 1.42 0.04 0.02 1.16 0.05 0.05 1.65 0.01 0.01 1.44 0.01 0.01 1.33 0.05 0.04 1.37 0.23 0.17
c-yes.70 mer 1.32 0.02 0.02 2.05 0.42 0.20 1.51 0.12 0.08 0.92 0.12 0.13 1.70 0.02 0.01 2.05 0.00 0.00 1.35 0.06 0.04 1.67 0.61 0.37
c-yes.2 0.45 0.05 0.10 0.11 0.03 0.32 n.d. 0.00 n.d. 0.00 0.05 0.01 0.28 0.13 0.01 0.11 0.08 0.01 0.11
MHCL.70 mer 1.73 0.05 0.03 0.48 0.13 0.27 1.57 0.07 0.05 0.80 0.01 0.01 1.69 0.02 0.01 0.04 0.04 1.18 1.27 0.02 0.02 1.10 0.62 0.55
HMBS.2 1.03 0.02 0.13 2.42 0.72 0.30 1.59 0.10 0.06 2.57 0.39 0.15 1.47 0.03 0.02 1.97 0.05 0.03 1.35 0.05 0.04 1.52 0.33 0.22
CV: coefficient of variation; n.d.: not detected.; SD: Standard deviation; bold letters indicate gene-sets that were considered to be constantly detectable across cell lines, and were selected to be used 
as normalization-set in further experiments. Probe sets that showed a CV < 0.6 were selected for the normalization housekeeping gene set.Virology Journal 2006, 3:43 http://www.virologyj.com/content/3/1/43
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EBNAs, three LMPs, and the non-coding EBERs can be
expressed in B-cells. Reactivation of EBV occurs via expres-
sion of its immediate early lytic gene BZLF1 and a subse-
quent cascade of gene activation [15].
A microarray targeting specific viral genes depends heavily
on selection strategy for the probe design. To accurately
monitor EBV transcription, we designed probes specific
for selected EBV genes: some from the latent phase (e.g.,
EBNA1, EBNA2, EBNA3A, EBNA3C, LMP1, and LMP2)
and some from lytic EBV infection (e.g., BZLF1/ Zta,
BXLF2/gp85, BKRF2/gL and BZLF2/gp42) (Table 1B). We
used B95.8 RNA as positive control and RNA from the
EBV-negative BL cell line BJAB as a negative control to
eliminate probes that cross-hybridize with cellular genes
(Fig. 1). RNAs from B95.8 and BJAB cells were compared
in self-vs-self experiments. EBV probes giving a signal with
B95.8 RNA but not with BJAB RNA were selected. We
tested three probes for EBNA1, EBNA2, and BXLF2/gp85
and two probes for LMP2 designed with either PE or AD
probe design software. All probes for EBNA1 had good
sensitivity and specificity, and the probes for EBNA2 and
BXLF2/gp85 designed with PE showed a nonspecific sig-
nal when hybridized to BJAB, as well as one of the EBNA2
probes designed with AD (EBNA2_AD2). To sample the
efficiency of the chip design, we also used the cell line
P3HR1, which has a deletion in the EBNA2 gene [16]. No
signal over background was detected with the EBNA2
probe (EBNA2_AD1) (Fig. 1C). These results indicate that
dedicated microarray design software and primer design
software can select for sensitive and specific probes but
not with 100% accuracy.
Comparison of quantitative EBV gene transcription 
profiling in a panel of BL cell lines
We next sought to compare quantitative EBV gene tran-
scription profiles in a panel of EBV-harboring BL cell lines.
The reference cell line B95.8 displays a latency III expres-
sion pattern, but about 5% of the cells display lytic EBV
infection. Thus, B95.8 is expected to transcribe both lytic
and latent genes. By selecting a set of housekeeping genes
that show the same specificity for human and marmoset
B-cell lines, we could use B95.8 RNA as a reference in
competitive hybridization experiments. RNAs extracted
from the EBV-positive BL cell lines Namalwa, Raji, Akata,
Jijoye, and P3HR1 were labeled and competitively hybrid-
ized against B95.8 labeled RNA in dye-swap experiments
(Cy3–Cy5) (Fig. 2).
We found that EBV gene transcription in all BL cell lines
tested was, in general, lower than in B95.8, as expected
(indicated by fold transcription levels equal or smaller
than 1 in Fig. 2). Consistent with our hypothesis, EBNA1
mean transcription levels were quite similar in the BL cell
lines: their transcription ratios to B95.8 ranged from 0.4
to 0.9 (a 2.25-fold difference), regardless of expected
latency I or switch to latency III, or episomal or integrated
status of EBV. Transcription levels of EBNA2 were highest
in Raji, reaching levels observed in B95.8. In Akata cells,
transcription levels of EBNA2 showed low absolute val-
Selection of microarray probes Figure 1
Selection of microarray probes. The specificity of EBV gene probes was tested in the reference cell line B95.8 as positive 
control (A) and in the EBV-negative cell line BJAB (B). The P3HR1 strain of EBV is characterized by a large deletion in the 
region coding for EBNA2 and was used to validate the specificity of EBNA2 probes (C). Black bars represent probes considered 
specific and selected for the final version of the chip. Mean ± SEM values (with background subtracted) were normalized to the 
set of eight housekeeping genes. Robust signals were measured for most latent and lytic EBV genes in the reference cell line 
B95.8. White bars indicate probes that were not selected.Virology Journal 2006, 3:43 http://www.virologyj.com/content/3/1/43
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Quantitative analysis of EBV gene transcription in cultured BL cell lines at steady state Figure 2
Quantitative analysis of EBV gene transcription in cultured BL cell lines at steady state. EBV gene transcription 
levels in exponentially growing cultured cells were determined by competitive hybridization to the reference cell line B95.8. 
Shown are mean ± SD values of dye-swap microarray experiments expressed as transcription ratio to B95.8. Dotted lines indi-
cate the range of mean transcription values. Stars represent "not detected."Virology Journal 2006, 3:43 http://www.virologyj.com/content/3/1/43
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ues, resulting in a greater SD than in the other cells lines.
This is in agreement with a latency I pattern, expected for
Akata. In P3HR1 cells, EBNA2 transcription was below
detection levels, as expected from the partial deletion of
the EBNA2 gene in the genomic EBV sequence present in
P3HR1. Mean transcription levels of EBNA2 in the other
BL cell lines ranged between 0.33 and 0.98 (a fourfold dif-
ference). Transcription levels of LMP1 among the BL cell
lines tested were highest in Jijoye, reaching levels twofold
higher than B95.8. LMP1  mean transcription ratios to
B95.8 in the BL cell lines ranged between 0.53 and 1.9 (a
3.6-fold difference). Absolute transcription levels for
Akata were very close to the detection limit (data not
shown), resulting in large SDs in the ratios to B95.8. Thus,
the results for LMP1 transcription in Akata should be con-
sidered as being negative. LMP2 transcription was not sig-
nificant in Namalwa and Akata cells. The levels for Raji,
Jijoye and P3HR1 were the same as in B95.8. Notably,
transcription values for B95.8 were close to saturation,
and therefore, the ratios appear especially compressed for
LMP2.
As expected, EBV lytic gene transcription was lower in the
selected BL cell lines than in B95.8. BZLF1 transcription
ratios varied between 0.1 and 0.6 (a sixfold range) and
were very low in all BL cell lines. In Namalwa and Raji
cells, transcription was 10% of that of B95.8 (i.e., at the
detection limit of microarray). Absolute transcription val-
ues of BZLF1  were lowest in Akata cells (not shown),
resulting in large SD in the ratios to B95.8. Similarly, tran-
scription levels of BXLF2 were significantly lower in all BL
cell lines than in B95.8, with ratios ranging form 0.3 to
0.5. The absolute values were close to the detection limit
for all cell lines (also for B95.8), resulting in large SD val-
ues, and the results must be considered essentially nega-
tive.
Thus, the BL cell lines exhibited no large differences in
their levels of EBNA1  gene transcription, regardless of
latency patterns that can switch from latency I to latency
III in vitro or integration status of the EBV genome. Tran-
scription levels of lytic EBV genes in BL cell lines were
lower than in B95.8, but among the BL cell lines tested,
transcription was high in producer cell lines (permissive)
such as Jijoye and P3HR1 and low (up to 10-fold) in
Namalwa (integrated EBV) and Raji (non-producer).
Validation of EBV microarray results by quantitative real-
time PCR
To validate the microarray results obtained by competitive
hybridization against the B95.8 cell line, RNAs extracted
from the EBV-positive BL cell lines Namalwa, Raji, Akata,
Jijoye, and P3HR1 were reverse-transcribed to cDNA, and
EBV gene transcription was measured with specific quan-
titative real-time PCR (qPCR) primers and probe systems.
The transcription values were normalized to the transcrip-
tion levels of HMBS, one of the normalization housekeep-
ing genes selected by microarray. HMBS  was chosen
instead of ACTB  because the transcription values (CT:
cycle threshold that quantifies the presence of target) of
the HMBS assay were closer to the values observed with
the EBV-specific qPCR assays (not shown) and therefore
should allow more accurate normalization.
Transcription data from the dedicated microarray were
compared to transcription data obtained from qPCR. To
allow this comparison, qPCR data, which were normal-
ized to HMBS  transcription, were transformed in tran-
scription ratio to B95.8 values (Fig. 3). Results from
microarray and qPCR were in good agreement when scor-
ing the EBV gene transcription levels as higher or as lower
than that in B95.8. However, some discrepancies were
observed in the absolute transcription differences. Results
from qPCR confirmed that transcription levels of EBNA1
do not significantly differ among the BL cell lines, except
in Namalwa. In Namalwa, transcription levels were 97%
lower from qPCR and about 50% lower measured by
microarray. The reasons for this discrepancy are not clear,
but they might be due to a polymorphism in the EBNA1
gene in Namalwa or, although transcription levels of
HMBS seemed constant, to the different normalization
procedures. Quantitative PCR confirmed microarray
results for EBNA2, except for Raji, in which transcription
levels were a 3.8-fold higher than in B95.8 by qPCR, and
similar to B95.8 by microarray.
Transcription levels of LMP1 showed the greatest discrep-
ancies between microarray and qPCR. Namalwa and
Jijoye were both confirmed by qPCR to transcribe LMP1 at
the same levels as B95.8. Transcription levels of LMP1 in
Akata and P3HR1 obtained by qPCR were only 10% of
those from the microarray, where the absolute transcrip-
tion levels for Akata were considered negative. In Raji,
transcription levels of LMP1 measured by qPCR were five-
fold higher than by microarray. The transcription levels of
LMP2 in Namalwa and Akata cell lines, undetectable by
microarray, were confirmed by qPCR, which detected
LMP2 at 10- to 20-fold lower levels, respectively. LMP2
transcription levels for Raji, Jijoye, and P3HR1 were simi-
lar to those for B95.8 by qPCR, again confirming the
microarray data. BZLF1 transcription was not detected in
Namalwa nor Raji cells and was detected at very low levels
in Akata, confirming microarray observations. Levels of
BZLF1 transcription measured by qPCR were lower (sev-
enfold) than measured by microarray (1.7-fold).BXLF2
transcription in Akata, Jijoye, and P3HR1 was confirmed
by qPCR to be twofold to fourfold lower than in B95.8.
BXLF2  transcription was not detected in Namalwa nor
Raji, indicating that the low ratios observed by microarray
are actually negative transcription values.Virology Journal 2006, 3:43 http://www.virologyj.com/content/3/1/43
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Thus, the qPCR results generally validated the microarray
results that transcription levels of EBNA1 did not signifi-
cantly differ among BL cell lines. The qPCR also con-
firmed the gene transcription patterns that indicate a
switch to latency III or permissiveness for lytic EBV infec-
tion. Importantly, these results show that the dedicated
EBV ODN chip is useful for quantifying latent and lytic
EBV gene transcription.
EBV gene transcription profiling upon induction of lytic 
infection in Akata cells
Finally, we wondered whether the chip would allow us to
record quantitative changes in EBV gene transcription
upon a treatment intervention. Lytic infection can be effi-
ciently induced by IgG cross-linking of the B-cell receptor
in Akata cells [17]. The key events are activation of the
master lytic EBV gene BZLF1 and expression of its product
Validation of microarray results by qPCR analysis Figure 3
Validation of microarray results by qPCR analysis. EBV gene transcription levels in exponentially growing cultured cells 
were determined by competitive hybridization to the reference cell line B95.8 and by qPCR. Shown are mean ± SD values from 
dye-swap microarray experiments (open squares) and for three independent qPCR experiments normalized over B95.8 
(closed triangles). Stars represent "not detected."Virology Journal 2006, 3:43 http://www.virologyj.com/content/3/1/43
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Zta [15]. Induction of lytic infection was confirmed by
detecting Zta protein expression by western blotting (Fig.
4A). As expected, Akata cells were negative for Zta before
induction, and the maximal expression level of Zta was
observed at 12 h after induction.
We then analyzed the simultaneous transcription of EBV
genes with the dedicated EBV microarray chip (Fig. 4B).
To quantify EBV gene transcription, RNA from treated
cells was competitively hybridized against RNA from non-
treated cells collected at the same time, with dye-swap.
Twofold or higher differences in transcription were arbi-
trarily considered significant changes when the standard
deviation was not above twofold. BZLF1 and BXLF2/gp85
were induced more than fivefold at 6 h, and their tran-
scription declined 48 h after treatment. Similarly, tran-
scription of BKRF2/gp42 and BZLF2/gL increased at 6 h,
peaked at 24 h, and declined at 72 h (not shown). The
latent genes, including EBNA2,  LMP2  and  EBNA3A,
EBNA3C  (not shown), were up-regulated more than
threefold 24 h after stimulation. Transcription of the
latent genes EBNA1 and LMP1 was up-regulated twofold
6 h after induction in Akata and persisted for 72 h with a
peak at 24 h. Akata cells unexpectedly exhibited a signifi-
cant increase in transcription levels of the latent EBV
genes. The increase of transcription of BZLF1 peaked at
sixfold over non-induced cells at 12 h and was terminated
when transcription of EBNA1,  EBNA2  and  LMP2
increased at 24 h after induction.
qPCR obtained the results from the microarray for tran-
scription profiles of EBV genes after B-cell receptor cross-
linking in Akata cells (Fig. 4C). Transcription of BZLF1
and BXLF2/gp85 was observed with qPCR also 6–12 h
after induction, followed by increases in levels of EBNA1,
EBNA2, and LMP2 gene transcription.LMP1 transcription
was also detected by qPCR at a significant level at 48 h
after induction, later than the increase of EBNA1, EBNA2,
and LMP2 24 h after induction. The increase in gene tran-
scription levels observed by qPCR was much larger (over
100-fold) than by microarray (about 10-fold).
In summary, transcription of lytic EBV genes and a slightly
deferred increase in transcription of latent genes upon
induction of lytic infection in Akata cells could be quanti-
tatively determined. This finding suggests that the dedi-
Effect of induction of lytic EBV infection on Zta and EBV gene transcription Figure 4
Effect of induction of lytic EBV infection on Zta and EBV gene transcription. (A) Western blot showing protein 
transcription levels of Zta in IgG cross-linking induced (+) and non-treated (-) Akata cells. (B) Transcription of EBV genes was 
quantified by microarray analysis in Akata cells upon induction of lytic infection. Treated and non-treated cells were harvested 
at different times after induction of lytic infection by BCR cross-linking. Competitive hybridization of labeled samples from 
treated cells was performed against non-treated cells. Shown are mean values of two dye-swap experiments. (C) EBV gene 
transcription was quantified during induction of lytic EBV infection in Akata cells by BCR cross-linking. For each time point, 
treated and non-treated cells were harvested and subjected to qPCR. Each point represents the difference between induced 
and non-induced cells, normalized to the HMBS housekeeping gene. Results are from at least two biological replicates and are 
given as: ΔΔCT = (CT(EBV gene)-CT(HMBS)}treated-{CT(EBV gene)-CT(HMBS))not treated.Virology Journal 2006, 3:43 http://www.virologyj.com/content/3/1/43
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cated EBV chip is suited for quantitative analysis of
simultaneous EBV gene transcription also after interven-
tions leading to alteration of gene expression.
Discussion
In this work, we report a novel assay system that quantita-
tively and simultaneously determines levels of transcrip-
tion of EBV genes. This system will contribute to an
improved understanding of EBV gene transcription regu-
lation and its impact on B-cell biology. Specifically, we
showed that (i) quantitative transcription of housekeep-
ing genes considerably differs between BL cell lines and
that selection of housekeeping genes appropriate for nor-
malization is an essential prerequisite to allow for com-
parison of quantitative EBV gene transcription between
cell lines; (ii) the transcription levels of EBNA1 in BL cell
lines do not significantly differ in contrast to transcription
levels of other EBV genes; and (iii) the dedicated EBV chip
is sensitive enough to detect EBV gene transcription
changes triggered by treatment interventions. Our results
suggest that EBNA1 transcription levels are uniform in BL
and that microarray analysis can reveal refined insights on
housekeeping and EBV gene transcription behavior.
A BL-specific housekeeping gene set
The importance of the choice of genes for data normaliza-
tion has become increasingly evident with the advent of
high-throughput gene-profiling technologies, such as
microarray and qPCR. A comprehensive literature analysis
of expression studies published in high-impact journals
during 1999 indicated that GAPDH, ACTB, 18S and 28S
rRNA were used as single control genes for normalization
in more than 90% of cases [12]. Because expression of
these genes can vary considerably [9,10], the validity of
the conclusions depends heavily on appropriate controls.
We defined a set of eight housekeeping genes with similar
transcription levels in the five BL cell lines tested and,
most importantly, in the marmoset LCL B95.8, the refer-
ence cell line for EBV. Seventeen housekeeping genes from
a compendium of 451 housekeeping genes expressed in
most tissues were tested them on a panel of BL cell lines.
Genes with the most or most constant expression and for
which a probe sequence was available in the compendium
for open-source human probes were selected [11]. Most
remarkably, the most highly expressed genes could not be
detected in all cell lines or gave the inconsistent results.
Fortunately, the most consistently expressed genes proved
to be much better, with a coefficient of variation lower
than 0.6. The best housekeeping gene in our set was ACTB,
which had the smallest coefficient of variation of all
genes.
Absolute quantification of gene transcription by micro-
array is accurate when enough probes are used to allow
global normalization (typically several thousands) or
when a reference is used to normalize results. On a micro-
array containing fewer than 1,000 elements, measure-
ments tend to be more variable than those from qPCR.
Nevertheless, the general overlap between microarray data
normalized over the set of housekeeping genes we
selected and qPCR data normalized over HMBS transcrip-
tion levels (part of the selected housekeeping set) indicate
that the housekeeping gene improves the accuracy of
results. Thus, the qualitative transcription profile
obtained with the housekeeping gene normalization set
was very close to that obtained by qPCR. Importantly, this
set of housekeeping genes will be useful in other micro-
array experiments since the cell lines are widely used to
study immunoglobulin rearrangements and other cellular
processes, such as DNA repair and apoptosis [18-22].
Validation of the dedicated EBV chip: advantages and 
disadvantages over qPCR
The dedicated EBV chip was validated by comparing
microarray and qPCR results. In general, the two tech-
niques agreed in distinguishing genes transcribed or not
transcribed, but some substantial differences occurred in
the quantitative assessment of gene transcription. Several
reasons might account for differences. First, the systems
do not target identical gene sequences, and differences in
the efficiency of reverse-transcription of mRNAs might
occur, even though we used the most homogeneous
design possible for all probes. Second, differences in the
amplitude of linear detection for microarray and qPCR (2
log10 vs 4 log10) might explain why microarray transcrip-
tion levels are more "compressed" than qPCR transcrip-
tion levels (i.e., microarray levels range from 0.1 to 10;
qPCR values range from 0.01 to 100).
The use of long ODN-based microarrays has two major
advantages over qPCR. The chip can be quickly expanded
to cover additional cellular genes, thereby decreasing the
cost per probe considerably. A microarray ODN chip can
easily accommodate up to 42,000 probes [23]. Another
advantage is the lower sensitivity to single nucleotide pol-
ymorphisms. The lower sensitivity could be considered a
disadvantage, but in the case of viruses which show a high
degree of polymorphism, it is an advantage. In fact, the
lower sensitivity helped in the present work. The BZLF1-
specific qPCR assay was designed using the B95.8
sequence, and one of the primers failed to work in Akata
cells because of a polymorphism at the 3' end of the
primer sequence (not shown). By contrast, the microarray
did not show a dramatic effect on the detection efficiency
between B95.8 and Akata, although the same polymor-
phism is within the sequence of the probe BZLF1.70 mer.
Therefore, microarray probes are more flexible and less
prone to false negative results than qPCR systems and thus
more suitable for transcription profiling of patient sam-Virology Journal 2006, 3:43 http://www.virologyj.com/content/3/1/43
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ples where multiple, not fully sequenced, EBV strains may
be present [24]. In conclusion, an EBV ODN microarray is
a valid alternative to qPCR and other techniques, espe-
cially for analysis of quantitative transcription of a large
number of genes or of patient samples, where the exact
sequence of the EBV strain is not known.
Transcription levels of EBNA1 do not differ significantly among BL 
cell lines
Qualitative expression of EBV genes has been extensively
studied, but our results are the first quantitative analysis.
The BL cell lines were selected to cover as many as charac-
teristics of EBV infection as possible. Notably, transcrip-
tion levels of EBNA1  are quite constant across BL cell
lines, despite differences in EBV genome integration sta-
tus, EBV type, EBV latency pattern or permissivity. This
observation suggests tight transcriptional control of
EBNA1, the gene mainly required for maintenance of the
episomal EBV genomes. Since Namalwa cells carry two
copies of EBV integrated in their genome and are expected
to display latency I expression pattern (only EBNA1),
transcription of EBNA1 might not be required for EBV
maintenance. The transcription levels, similar to those in
the BL cell lines with episomal EBV, could indicate that
EBNA1 transcription is needed for other functions, such
as cell proliferation. The low transcription levels of
EBNA2 and LMPs and the absence of lytic gene transcrip-
tion in Namalwa confirm its tight latency pattern I expres-
sion. In Raji cells, also expected to express latency I, we
observed a switch to latency III, with transcription of
EBNA2 and LMP1 at the same levels observed in B95.8. Of
course, due to the limited number of BL cell lines investi-
gated, no conclusions can be drawn. Nevertheless, the val-
idated microarray will make it possible to further
investigate transcription levels of EBV genes, their correla-
tion with cellular gene transcription, and the mechanisms
regulating translation of EBV genes into proteins, all cru-
cial steps allowing EBV to hide from the immune system
and persist for life in host B-cells.
Transcription levels of latent EBV genes increase upon 
induction of lytic infection
Induction of lytic infection by B-cell receptor cross-linking
of Akata cells resulted in increased transcription levels of
latent EBV genes, which peaked concomitantly with ter-
mination of increased BZLF1 gene transcription and pro-
tein expression. This result comes partially as a surprise:
the extent and kinetic of increase of latent EBV gene tran-
scription have not been described in a quantitative man-
ner. Previous work had shown that translation of EBNA1,
EBNA2, and LMP1 increased after induction of lytic infec-
tion [25]. An increase in LMP2  expression was also
observed in Akata cells by Southern reverse transcription
PCR [25], but our analysis of the kinetics of latent EBV
genes transcription indicates that their transcription is
increased concomitantly with early lytic EBV genes.
EBNA2 can induce lytic infection in Akata cells under
some circumstances [26], but LMP1 [27] and LMP2 [28]
exert a negative effect on induction of lytic infection. From
the microarray data, one might hypothesize a novel mech-
anism in which transcription of latent genes regulates acti-
vation of lytic infection.
Conclusion
Using a newly developed dedicated EBV microarray ODN
chip containing a set of carefully selected housekeeping
genes for data normalization, we defined the quantitative
profile of EBV gene transcription of a panel of BL cell
lines. Furthermore, we showed that EBNA1 transcription
levels are similar across BL cell lines, suggesting tight tran-
scriptional control of EBNA1. Finally, we showed that the
dedicated EBV chip can be used to monitor quantitative
latent and lytic EBV gene transcription after induction of
lytic EBV infection. The ability to quantify EBV gene tran-
scription will allow studies of EBV gene translation. This
result is particularly important for considering EBV as a
target for therapies of EBV-positive tumors. The selected
housekeeping gene sequences and EBV-specific sequences
can be easily incorporated in other dedicated microarrays
and will be useful for studies of cellular and EBV gene
transcription profiles.
Methods
Cell lines
As a reference for EBV gene transcription, we used the
EBV-positive B95.8 cell line, an LCL of marmoset origin
that expresses latent and lytic EBV genes both constitu-
tively and concomitantly. The EBV-negative BL cell line
BJAB served as negative control. To characterize quantita-
tive EBV gene transcription, we chose a panel of EBV-har-
boring BL cell lines with different characteristics. The
panel included three BL cell lines with EBV type I virus:
Namalwa [29], Raji [30] (50 copies of EBV per cell [31]
with a deletion in EBNA3-C [32], and Akata [26] (20 cop-
ies of EBV per cell). It also contained two BL cell lines with
EBV type II virus: Jijoye and its daughter cell line P3HR1,
which has a deletion in EBNA2. Cells infected with EBV
type I and type II exhibit different transformation and out-
growth potentials [33]. Jijoye and P3HR1 are EBV-produc-
ing cell lines, Akata cells can be induced to produce EBV,
and Raji and Namalwa cells do not produce EBV particles.
Furthermore, in Namalwa cells, the EBV genome is inte-
grated in the human chromosome [34], while the other
BL cell lines harbor the virus in episomal form. Finally,
although BL cells in culture initially display an EBV
latency I pattern as BL cells do ex vivo, some BL cell lines
(e.g., Raji) may switch to a latency III pattern upon contin-
ued in vitro culture, and others (e.g., Namalwa) do not.
Akata was a kind gift from Dr. A. Bell (Birmingham, UK);
all other cell lines were from ATCC (Rockville, MD). CellsVirology Journal 2006, 3:43 http://www.virologyj.com/content/3/1/43
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were cultivated in RPMI 1640 with 10% fetal bovine
serum at 37°C and in 5% CO2 humidified atmosphere.
Induction of lytic EBV infection
Lytic EBV infection was induced by cross-linking of sur-
face immunoglobulin with anti-IgG as follows. For 3 h,
106  Akata cells were incubated with 100 μg/ml anti-
human IgG (Dako A0423, DakoCytomation, Zug, Swit-
zerland), and after a medium change, the cells were plated
on 24-well plates [7]. Cells were harvested before and at
different times after stimulation and subjected to total
RNA extraction or western blotting. Control cells were
handled in the same way as the test cells but not incubated
with anti-human IgG.
Isolation, amplification, and labeling of nucleic acids
For experiments that induced lytic EBV infections, total
RNA was isolated from cells with RNeasy midi kit or mini
kit (Qiagen, Basel, Switzerland), according to the manu-
facturer's instructions. Limiting amounts of total RNA (1
μg) were amplified and then labeled with the amino allyl
MessageAmp aRNA Kit (Ambion Europe, Huntingdon,
UK). Indirect amino allyl labeling was performed with
CyScribe Post-Labeling Kit (Amersham Bioscience,
Dübendorf, Switzerland). Cy-dyes incorporation was
measured with Nanodrop-1000 (NanoDrop Technolo-
gies, Wilmington, DE, USA). The validity of the amplifica-
tion protocol was tested by competitive hybridization of
cRNA from the reference cell line B95.8 labeled with Cy3
vs B95.8 cRNA labeled with Cy5. Both labeled cRNAs were
obtained with the direct labeling protocol (non-ampli-
fied). A significant correlation factor was observed
between amplified and non-amplified samples (R = 0.95).
Design of probes and array fabrication
Sequences for some housekeeping genes were derived
from the Church's published set of array probes [11].
Probes were designed either using the Primer Express soft-
ware (PE, Applied Biosystems, Rotkreuz, Switzerland),
with parameters: 40–60% GC content, Tm 70–90°C, and
lack of homo-oligomers and sequence repeats (labeled
gene-name.70 mer), or the ArrayDesigner 2 (AD, Premiere
Biosoft International, Palo Alto, CA, USA) with parame-
ters: 60–70 nucleotides (nt), distance from 3,500 nt or
1,000 nt (labeled gene-name_AD). Probes were designed
to be as close to the 3' end as possible, distances from 3'
ranging from 20 nt to 1500 nt (median 407 nt). Probes Tm
ranged between 75°C and 95°C (median 77.7°C); GC
content ranged from 40% to 60% (median 51.6%). (For
details, see Table 1.) 5' Amino C6 PAGE-purified probes
were synthesized by Sigma-Genosys (Pampisford, UK).
Slides coated with 3-glycidoxypropyl-trimethyl silane
("epoxysilane") were obtained from Scienion (Berlin,
Germany). 20 μM solutions of ODN in 3 × SSC were spot-
ted using a Biochip Arrayer later a Piezorray (both from
PerkinElmer Life Sciences, Seer Green, UK). 3 droplets
(about 1 nL) were deposited at the slide surface. ODNs
were immobilized in a humidity chamber (23°C, 75%
relative humidity) over night.
Microarray hybridizations
Hybridizations were performed in an automated hybridi-
zation station (HS4800, Tecan, Salzburg, Austria) for 16 h
at 42°C. Slides were washed with 2 × SSC/0.2% SDS, 0.2
× SSC/0.2% SDS, finally 0.2 × SSC, and dried in the
machine with a flow of nitrogen.
Microarray experiments and analysis of data
The reproducibility of microarray results was tested by
performing a set of experiments in which RNA isolated
from the same cell line was labeled with either Cy3 or Cy5
and then competitively hybridized (self vs self). The cor-
relation coefficient (R) of self vs self hybridization was
0.96–0.99. Slides were scanned at decreasing laser power
(70, 60, 50, 40, and 30 db) with an Affymetrix 427 laser
scanner (MWG Biotech, Ebersberg, Germany). Spot inten-
sities from TIFF (Tagged Image File Format) files were ana-
lyzed with ImaGene 5.0 software and imported in
GeneSight 3.2 software (BioDiscovery, El Segundo, CA,
USA). Local backgrounds of spot intensities were averaged
and subtracted (median). Cy3 and Cy5 intensities were
corrected by normalization (division by the median of the
housekeeping genes). Replicate spots were processed sin-
gularly and combined after ratios were calculated (mean ±
SEM). Ratios between competitive hybridizations repre-
sent the mean value of dye-swap experiments. When more
than one probe per gene was used, the mean value (±
SEM) of all probes was calculated.
Quantitative real-time PCR assays of EBV gene 
transcription
For qPCR assays of EBV gene transcription analysis, 1 μg
of total RNA was reverse transcribed with oligo-dT (15)
and Omniscript reverse transcriptase (Qiagen, Basel, Swit-
zerland). The design and validation of the primers and
probes specific for EBV were as described (Berger C, Bona-
nomi A, Ladell K, Nadal D. submitted for publication).
Probes were labeled with 5'6-carboxyfuorescein (FAM)
and 3' Black Hole Quencher (BHQ, Biosearch Technolo-
gies, Novato, CA, USA). qPCR was performed in a reaction
volume of 15 μl with the ABI-TaqMan Master Mix with
uracil-N-glycosylase (Applied Biosystems, Rotkreuz, Swit-
zerland) [35]. The normalized transcription values corre-
spond to 2-C
T
(EBV)-C
T
(HMBS) = 2-ΔC
T, where CT is the cycle
threshold number that quantifies the target present.
Western blotting
For western blotting, cells were lysed using a syringe in
lysis buffer (125 mM Tris-HCl, pH 6.8, 6% SDS). The pro-
teins were separated by electrophoresis on a 10% Bis-TrisVirology Journal 2006, 3:43 http://www.virologyj.com/content/3/1/43
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gel (Invitrogen, Basel, Switzerland). For immunoblotting,
the following antibodies and dilutions were used: anti-
EBV Z Replication Activator (ZEBRA, Zta), clone AZ-69
(1:100 dilution, Argene Biosoft, Varilhes, France), the
monoclonal rat-anti LMP2A, (clone TP 14B7, 1:100 dilu-
tion, Ascenion, Germany), the mouse anti EBNA2 (Dako-
Cytomation, Baar, Switzerland), and the PCNA (BD
Bioscience, Basel, Switzerland). Antibodies were visual-
ized with ECL Western Blotting Detection Reagent (Amer-
sham Bioscience, Dübendorf, Switzerland).
Abbreviations
AD, ArrayDesign software; BL, Burkitt's lymphoma; CT,
cycle threshold; CV, coefficient of variation; EBV, Epstein-
Barr virus; LCL, lymphoblastoid cell line; LMP, latent
membrane protein; ODN, oligonucleotide; PCR,
polymerase chain reaction; PE, Primer Express software;
qPCR, quantitative real-time polymerase chain reaction;
SD, standard deviation.
Competing interests
The author(s) declare that they have no competing inter-
ests.
Authors' contributions
MB, CB, FKN, and DN conceived the study and designed
the experiments. MB, CB, JAS, JS, and AB participated in
the experimental data collection. MB analyzed the data.
MB, CB, and DN drafted the manuscript.
Acknowledgements
This work was supported by grants from the Swiss Bridge Foundation and 
the Cancer League of the Kanton of Zurich. We thank Nicole Köchli for 
technical assistance with cells and TaqMan experiments and Valentino Cat-
tori for assistance with ODN selection.
References
1. Cohen JI: Epstein-Barr virus infection.  N Engl J Med 2000,
343(7):481-492.
2. Sugimoto M, Tahara H, Ide T, Furuichi Y: Steps involved in immor-
talization and tumorigenesis in human B-lymphoblastoid cell
lines transformed by Epstein-Barr virus.  Cancer Res 2004,
64(10):3361-3364.
3. Ambinder RF, Robertson KD, Moore SM, Yang J: Epstein-Barr
virus as a therapeutic target in Hodgkin's disease and
nasopharyngeal carcinoma.  Semin Cancer Biol 1996,
7(4):217-226.
4. Kieff E, Rickinson AB: Epstein-Barr virus and its replication.  In
Fields Virology Volume 2. Fourth edition. Edited by: Knipe DM, Howley
PM. Philadelphia, PA , Lippincott Williams & Wilkins Publishers;
2001:2511-2573. 
5. Kelly G, Bell A, Rickinson A: Epstein-Barr virus-associated
Burkitt lymphomagenesis selects for downregulation of the
nuclear antigen EBNA2.  Nat Med 2002, 8(10):1098-1104.
6. Chang YN, Dong DL, Hayward GS, Hayward SD: The Epstein-Barr
virus Zta transactivator: a member of the bZIP family with
unique DNA-binding specificity and a dimerization domain
that lacks the characteristic heptad leucine zipper motif.  J
Virol 1990, 64(7):3358-3369.
7. Takada K, Ono Y: Synchronous and sequential activation of
latently infected Epstein-Barr virus genomes.  J Virol 1989,
63(1):445-449.
8. Feng WH, Hong G, Delecluse HJ, Kenney SC: Lytic induction ther-
apy for Epstein-Barr virus-positive B-cell lymphomas.  J Virol
2004, 78(4):1893-1902.
9. Hsiao LL, Dangond F, Yoshida T, Hong R, Jensen RV, Misra J, Dillon
W, Lee KF, Clark KE, Haverty P, Weng Z, Mutter GL, Frosch MP,
Macdonald ME, Milford EL, Crum CP, Bueno R, Pratt RE,
Mahadevappa M, Warrington JA, Stephanopoulos G, Gullans SR: A
compendium of gene expression in normal human tissues.
Physiol Genomics 2001, 7(2):97-104.
10. Warrington JA, Nair A, Mahadevappa M, Tsyganskaya M: Compari-
son of human adult and fetal expression and identification of
535 housekeeping/maintenance genes.  Physiol Genomics 2000,
2(3):143-147.
11. Wright MA, Church GM: An open-source oligomicroarray
standard for human and mouse.  Nat Biotechnol 2002,
20(11):1082-1083.
12. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De
Paepe A, Speleman F: Accurate normalization of real-time
quantitative RT-PCR data by geometric averaging of multi-
ple internal control genes.  Genome Biology 2002,
3(7):research0034.1 - research0034.11.
13. Gradoville L, Kwa D, El-Guindy A, Miller G: Protein kinase C-inde-
pendent activation of the Epstein-Barr virus lytic cycle.  J Virol
2002, 76(11):5612-5626.
14. de Jesus O, Smith PR, Spender LC, Elgueta Karstegl C, Niller HH,
Huang D, Farrell PJ: Updated Epstein-Barr virus (EBV) DNA
sequence and analysis of a promoter for the BART (CST,
BARF0) RNAs of EBV.  J Gen Virol 2003, 84(Pt 6):1443-1450.
15. Sinclair AJ: bZIP proteins of human gammaherpesviruses.  J
Gen Virol 2003, 84(Pt 8):1941-1949.
16. Miller G, Robinson J, Heston L, Lipman M: Differences between
laboratory strains of Epstein-Barr virus based on immortali-
zation, abortive infection, and interference.  Proc Natl Acad Sci
U S A 1974, 71(10):4006-4010.
17. Daibata M, Humphreys RE, Takada K, Sairenji T: Activation of
latent EBV via anti-IgG-triggered, second messenger path-
ways in the Burkitt's lymphoma cell line Akata.  J Immunol
1990, 144(12):4788-4793.
18. Bertolini F, Dell'Agnola C, Mancuso P, Rabascio C, Burlini A, Monesti-
roli S, Gobbi A, Pruneri G, Martinelli G: CXCR4 neutralization, a
novel therapeutic approach for non-Hodgkin's lymphoma.
Cancer Res 2002, 62(11):3106-3112.
19. Jurisic V, Bogdanovic G, Kojic V, Jakimov D, Srdic T: Effect of TNF-
alpha on Raji cells at different cellular levels estimated by
various methods.  Ann Hematol 2005:1-9.
20. Kawabata Y, Hirokawa M, Kitabayashi A, Horiuchi T, Kuroki J, Miura
AB: Defective apoptotic signal transduction pathway down-
stream of caspase-3 in human B-lymphoma cells: A novel
mechanism of nuclear apoptosis resistance.  Blood 1999,
94(10):3523-3530.
21. Schmitz F, Mages J, Heit A, Lang R, Wagner H: Transcriptional acti-
vation induced in macrophages by Toll-like receptor (TLR)
ligands: from expression profiling to a model of TLR signal-
ing.  Eur J Immunol 2004, 34(10):2863-2873.
22. Yao L, Pike SE, Pittaluga S, Cherney B, Gupta G, Jaffe ES, Tosato G:
Anti-tumor activities of the angiogenesis inhibitors inter-
feron-inducible protein-10 and the calreticulin fragment
vasostatin.  Cancer Immunol Immunother 2002, 51(7):358-366.
23. Auburn RP, Kreil DP, Meadows LA, Fischer B, Matilla SS, Russell S:
Robotic spotting of cDNA and oligonucleotide microarrays.
Trends Biotechnol 2005, 23(7):374-379.
24. Sitki-Green D, Edwards RH, Webster-Cyriaque J, Raab-Traub N:
Identification of Epstein-Barr virus strain variants in hairy
leukoplakia and peripheral blood by use of a heteroduplex
tracking assay.  J Virol 2002, 76(19):9645-9656.
25. Rowe M, Lear AL, Croom-Carter D, Davies AH, Rickinson AB:
Three pathways of Epstein-Barr virus gene activation from
EBNA1-positive latency in B lymphocytes.  J Virol 1992,
66(1):122-131.
26. Fujiwara S, Nitadori Y, Nakamura H, Nagaishi T, Ono Y: Epstein-
Barr Virus (EBV) Nuclear Protein 2-Induced Disruption of
EBV Latency in the Burkitt's Lymphoma Cell Line Akata:
Analysis by Tetracycline-Regulated Expression.  J Virol 1999,
73(6):5214-5219.
27. Prince S, Keating S, Fielding C, Brennan P, Floettmann E, Rowe M:
Latent membrane protein 1 inhibits Epstein-Barr virus lyticPublish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Virology Journal 2006, 3:43 http://www.virologyj.com/content/3/1/43
Page 15 of 15
(page number not for citation purposes)
cycle induction and progress via different mechanisms.  J Virol
2003, 77(8):5000-5007.
28. Miller CL, Lee JH, Kieff E, Longnecker R: An integral membrane
protein (LMP2) blocks reactivation of Epstein-Barr virus
from latency following surface immunoglobulin crosslinking.
Proc Natl Acad Sci U S A 1994, 91(2):772-776.
29. Klein G, Dombos L, Gothoskar B: Sensitivity of Epstein-Barr
virus (EBV) producer and non-producer human lymphoblas-
toid cell lines to superinfection with EB-virus.  Int J Cancer 1972,
10(1):44-57.
30. Epstein MA, Achong BG, Barr YM, Zajac B, Henle G, Henle W: Mor-
phological and virological investigations on cultured Burkitt
tumor lymphoblasts (strain Raji).  J Natl Cancer Inst 1966,
37(4):547-559.
31. Marshall NA, Howe JG, Formica R, Krause D, Wagner JE, Berliner N,
Crouch J, Pilip I, Cooper D, Blazar BR, Seropian S, Pamer EG: Rapid
reconstitution of Epstein-Barr virus-specific T lymphocytes
following allogeneic stem cell transplantation.  Blood 2000,
96(8):2814-2821.
32. Maunders MJ, Petti L, Rowe M: Precipitation of the Epstein-Barr
virus protein EBNA 2 by an EBNA 3c-specific monoclonal
antibody.  J Gen Virol 1994, 75 ( Pt 4):769-778.
33. Rickinson AB, Young LS, Rowe M: Influence of the Epstein-Barr
virus nuclear antigen EBNA 2 on the growth phenotype of
virus-transformed B cells.  J Virol 1987, 61(5):1310-1317.
34. Henderson A, Ripley S, Heller M, Kieff E: Chromosome site for
Epstein-Barr virus DNA in a Burkitt tumor cell line and in
lymphocytes growth-transformed in vitro.  Proc Natl Acad Sci U
S A 1983, 80(7):1987-1991.
35. Bonanomi A, Kojic D, Giger B, Rickenbach Z, Jean-Richard-Dit-Bres-
sel L, Berger C, Niggli FK, Nadal D: Quantitative cytokine gene
expression in human tonsils at excision and during histocul-
ture assessed by standardized and calibrated real-time PCR
and novel data processing.  J Immunol Methods 2003, 283(1-
2):27-43.